Alcoholic fatty liver disease

Summary

Alcoholic fatty liver disease (MONDO:0021104) is a disease and 2 clinical trials. Top therapeutic interventions include pyridoxine. A subtype of fatty liver disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	alcoholic fatty liver disease
Mondo ID	MONDO:0021104
MeSH	D005235
ICD-10-CM	K70.0
ICD-11	1759668616
SNOMED CT	50325005
UMLS	C0015696
MedGen	4666
Is cancer (heuristic)	no

Also known as: alcoholic fatty liver · alcoholic Steatohepatitis

Disease family

This is a subtype of fatty liver disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › fatty liver disease › alcoholic fatty liver disease

Related subtypes (3): visceral steatosis, congenital, metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol associated liver disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pyridoxine.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07466485	PHASE2	NOT_YET_RECRUITING	The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)
NCT02019056	PHASE2	COMPLETED	Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PYRIDOXINE	4	1